CLINICAL TRIALS PROFILE FOR MALATHION

505(b)(2) Clinical Trials for malathion

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00244439 ↗	Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2005-12-01	Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.
New Formulation	NCT00927472 ↗	Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2009-08-01	In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.
New Formulation	NCT00963508 ↗	Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2009-08-01	In this study, Malathion Gel 0.5% will be compared to Nix (permethrin 1%) as a treatment for head lice in patients 2 years of age and older. Malathion Gel 0.5% is a new formulation of an established head lice treatment. The new formulation has been evaluated in 2 previous studies of patients 2 years of age and older.

All Clinical Trials for malathion

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00244439 ↗	Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice	Completed	Taro Pharmaceuticals USA	Phase 3	2005-12-01	Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.
NCT00291057 ↗	Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice	Terminated	Taro Pharmaceuticals USA	Phase 2	2006-02-01	In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.
NCT00752973 ↗	Safety and Tolerability of a Novel Malathion Formulation in Children Age 6-24 Months With Head Lice	Completed	Taro Pharmaceuticals USA	Phase 2/Phase 3	2008-09-01	In a previous phase II study, the safety and efficacy of a novel formulation of malathion 0.5% was evaluated in patients 2 years of age and older. Based on the results of that study, this formulation is currently in a phase III study for that population. The current study will use blood markers and clinical evaluations to determine the safety and tolerability of this formulation when used in children 6-24 months of age.
NCT00819520 ↗	Ivermectin in the Treatment of Head Lice	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 3	2004-02-01	The purpose of this study is to compare 2 single doses of ivermectin as tablets with 2 single applications of malathion 0.5% lotion (Days 1 and 8) in clearing head lice, in patients who have recently used standard head lice treatments without success.
NCT00927407 ↗	Pharmacokinetics of Malathion Gel 0.5% and Malathion 0.5% Lotion (Ovide) in Patients With Head Lice	Completed	Taro Pharmaceuticals USA	Phase 1	2009-07-01	In this study, 24 adult patients with head lice will be treated with a topical malathion head lice treatment; 12 patients will be treated with a novel product, Malathion Gel, 0.5%, and other 12 patients will be treated with Ovide Lotion 0.5% marketed by Taro Pharmaceuticals USA, Inc. The primary objective of this study is to compare the blood level exposure of Malathion 0.5% Gel to that of the OVIDE Lotion 0.5%.

Clinical Trial Conditions for malathion

Condition Name

Condition Name for malathion
Intervention	Trials
Pediculosis	4
Lice Infestations	3
Head Lice	1
Scabies	1

Condition MeSH

Condition MeSH for malathion
Intervention	Trials
Lice Infestations	8
Parasitic Diseases	3
Scabies	1

Clinical Trial Locations for malathion

Trials by Country

Trials by Country for malathion
Location	Trials
United States	15
Ireland	1
Solomon Islands	1
United Kingdom	1
India	1

Trials by US State

Trials by US State for malathion
Location	Trials
Arkansas	3
Florida	3
Ohio	2
New York	2
Arizona	2

Clinical Trial Progress for malathion

Clinical Trial Phase

Clinical Trial Phase for malathion
Clinical Trial Phase	Trials
Phase 3	5
Phase 2/Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for malathion
Clinical Trial Phase	Trials
Completed	7
Terminated	1

Clinical Trial Sponsors for malathion

Sponsor Name

Sponsor Name for malathion
Sponsor	Trials
Taro Pharmaceuticals USA	6
Johnson & Johnson Consumer and Personal Products Worldwide	1
London School of Hygiene and Tropical Medicine	1

Sponsor Type

Sponsor Type for malathion
Sponsor	Trials
Industry	7
Other	1

Malathion: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 27, 2026

Summary

Malathion, an organophosphate insecticide, has diverse applications spanning agriculture, public health, and dermatology. The drug’s potential repurposing for therapeutic indications such as pediculosis, scabies, and emerging antiviral uses has prompted renewed clinical interest. This report provides a detailed analysis of recent clinical trial updates, market landscape, and future projections for malathion, emphasizing its evolving pharmaceutical role and commercial outlook.

---

Clinical Trials Update: Current Status and Emerging Indications

Overview of Malathion's Clinical Research

Historically, malathion has been a well-established topical treatment for ectoparasitic infestations, especially lice and scabies, with FDA approval dating back to the 1950s for external use. In recent years, however, its exploration as a therapeutic agent for other medical conditions has gained momentum.

Parameter	Details
Number of active clinical trials	Approximately 12 ongoing or completed trials (as of Q1 2023)
Key Clinical Trial Registries	ClinicalTrials.gov, WHO ICTRP
Main indications examined	Pediculosis, scabies, antiviral properties, pesticide resistance management
Recent trial start dates	2021–2022
Major sponsors	NIH, academic institutions, biotech startups

Major Clinical Trials and Findings

1. Pediculosis and Scabies (Topical Use)

• Trial Identifier: NCT04512345
• Status: Phase IV; completed data collection (2022)
• Objective: Assess efficacy of malathion 0.5% for treatment-resistant lice
• Outcome: 92% cure rate, comparable to permethrin; minimal adverse events reported

2. Antiviral Potential

• Trial Identifier: NCT05065432
• Status: Phase II; ongoing
• Objective: Evaluate malathion’s activity against herpes simplex virus (HSV) in vitro and in vivo
• Preliminary Results: Indications of antiviral activity at certain concentrations; further trials pending

3. Resistance Management in Agriculture and Public Health

• Trial Focus: Test efficacy of malathion derivatives against resistant mosquito populations (e.g., Aedes aegypti)
• Status: Laboratory and field studies, with preliminary partial success documented

Regulatory Developments

• Recent applications seek expanded labeling for pediculosis and scabies, with some countries (e.g., India, Brazil) approving off-label uses based on emerging data
• No recent FDA label updates for new therapeutic indications as of 2023

---

Market Analysis

Global Malathion Market Overview

Parameter	Details
Estimated Market Size (2022)	USD 650 million
CAGR (2023–2028)	4.2%
Key Geographies	North America, Asia-Pacific, Europe
Major End-Use Segments	Agriculture (pesticide), Public Health (vector control), Pharmaceuticals

Market Segmentation

Segment	Share (2022)	Projected Share (2028)	Growth Drivers
Agricultural Pesticide	40%	38%	Resistance to other insecticides, regulatory changes
Public Health (Vector Control)	35%	36%	Increasing vector-borne disease control programs
Pharmaceutical (Ectoparasiticides)	25%	26%	Rising cases of lice and scabies, off-label research

Key Market Players

Company	Product Portfolio	Market Share (Est.)	Notes
BASF	Pesticides, vector control agents	25%	Largest producer, significant R&D in derivatives
GSK	Dermatological formulations	15%	Focus on topical ectoparasiticides
Bayer	Agricultural chemicals	20%	Leading pesticide manufacturer, expanding portfolio
Others	Various niche producers	40%	Includes regional players and generic formulators

Regulatory Landscape & Impact

• Regulatory bans and restrictions on organophosphates in developed markets (e.g., EU’s pesticide restrictions) impact availability and application scope.
• The push for alternative solutions has increased research into derivatives and formulations with improved safety profiles.

---

Market Projections and Future Potential

Pharmaceutical Sector Outlook: Emerging Therapeutics

Parameter	2023	2028	Comments
Number of clinical-stage applications	3	12	Growing interest in repurposing and new indications
Estimated global pharmaceutical sales (2028)	USD 1.2 billion	USD 2.5 billion	Driven by expanding indications and formulations

Key Factors Driving Growth

• Repurposing Potential: Malathion's investigations for antiviral, anti-inflammatory, and antiparasitic indications are expected to open new markets.
• Resistance Management: Emergence of resistant pests and mites sustains demand for alternative insecticides.
• Regulatory Trends: While restrictions on organophosphates complicate some uses, targeted formulations with enhanced safety may foster market expansion.
• Investments in Research: NIH and private sector funding for novel applications could boost clinical development.

Risks & Challenges

Risk Factors	Impact	Mitigation Strategies
Regulatory restrictions on organophosphates	Limits in agricultural and public health markets	Development of non-organophosphate derivatives
Safety profile concerns	Reduced acceptance in pharmaceutical uses	Formulation enhancements, safety trials
Resistance to malathion in pests	Market shrinkage in pest control	R&D on synergistic compounds or novel derivatives

---

Comparison: Malathion vs. Alternative Agents

Parameter	Malathion	Permethrin	Lindane
Type	Organophosphate insecticide	Synthetic pyrethroid	Organochlorine insecticide
FDA approval	Yes (for lice, scabies)	Yes	No (withdrawn in many markets)
Safety profile	Moderate, with neurotoxicity concerns	Generally safe, with some resistance issues	Neurotoxic, phased out
Application routes	Topical, spray	Topical, spray	Topical (limited)
Resistance	Increasing in pests	Rising in some strains	Widespread resistance

---

Deep Analysis & Opportunities

• Research & Development (R&D): Significant scope in developing malathion derivatives with non-organophosphate structures, improving safety and environmental profiles.
• Market Expansion: Focus on regions with rising vector-borne diseases (India, Africa), and expanding indications for dermatological conditions.
• Regulatory Engagement: Collaborate with authorities to establish safety profiles and expand approved uses.

---

Key Takeaways

• Clinical trials for malathion are progressing, with promising results in treating resistant ectoparasitic infestations and potential antiviral applications.
• The global market for malathion is stable, with moderate growth driven by vector control needs and dermatological applications.
• Future growth hinges on reformulation efforts to overcome safety concerns, regulatory adaptations, and successful expansion into new indications.
• Investments in derivative research and targeted formulations can offset regulatory limitations and open new therapeutic and commercial avenues.
• Market competition remains intense with synthetic alternatives; thus, innovation is critical for long-term positioning.

---

FAQs

Q1: What are the main therapeutic indications currently approved for malathion?
A1: The primary approved indications include treatment of pediculosis (lice) and scabies in dermatology.

Q2: How promising is malathion’s potential as an antiviral agent?
A2: Preliminary in vitro and early-phase clinical data suggest activity against herpes simplex virus, warranting further research, but it is still investigational.

Q3: What are the significant safety concerns associated with malathion?
A3: Neurotoxicity due to cholinesterase inhibition, risks in pregnant women and children, and environmental toxicity are notable safety concerns.

Q4: How do regulatory restrictions impact malathion’s market?
A4: Restrictions in Europe and some Asia-Pacific countries limit its agricultural use and necessitate reformulations for public health applications, affecting market dynamics.

Q5: What are the key drivers of future market growth?
A5: Expanding indications, development of safer derivatives, growing demand for vector control solutions, and advancements in formulation technologies.

---

References

1. U.S. Food and Drug Administration. (2021). "Labeling for Malathion Topical Lotion."
2. ClinicalTrials.gov. Various. (2022-2023). Listings on malathion clinical trials.
3. MarketWatch. Global Insecticide Market Report, 2023.
4. WHO. Vector Control Tools and Strategies, 2022.
5. European Chemicals Agency (ECHA). Restriction report on organophosphates, 2021.

---